难治乳腺癌患者疾病风险降低46% HER2特异性TKI达3期临床终点(2)
2020-02-20 未知 admin
[1] Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer, Retrieved October 21, 2019, from https://www.businesswire.com/news/home/20191021005169/en/
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。▽关注【药明康德】微信公众号
鐑瘝锛